Immunogenic cell death and bystander killing: expanding the therapeutic potential of modern antibody-drug conjugates.

IF 6.5 2区医学 Q1 IMMUNOLOGY

Oncoimmunology Pub Date : 2025-12-01 Epub Date: 2025-07-15 DOI:10.1080/2162402X.2025.2533488

Oliver Kepp, Guido Kroemer

引用次数: 0

Abstract

HER3-DXd and T-DXd are antibody-drug conjugates (ADCs) that induce immunogenic cell death and bystander killing, enhancing antitumor immunity beyond target-specific cytotoxicity. These findings highlight novel mechanisms that can overcome antigen heterogeneity and suggest opportunities for improving ADC design and therapeutic synergy through informed combination with immunotherapies.

Abstract Image

查看原文本刊更多论文

免疫原性细胞死亡和旁观者死亡：扩大现代抗体-药物偶联物的治疗潜力。

HER3-DXd和T-DXd是抗体-药物偶联物（adc），可诱导免疫原性细胞死亡和旁观者杀伤，增强抗肿瘤免疫，超越靶向性细胞毒性。这些发现强调了克服抗原异质性的新机制，并提出了通过与免疫疗法的明智结合来改进ADC设计和治疗协同作用的机会。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Oncoimmunology ONCOLOGYIMMUNOLOGY-IMMUNOLOGY

CiteScore

12.50

自引率

2.80%

发文量

276

审稿时长

24 weeks

期刊介绍： OncoImmunology is a dynamic, high-profile, open access journal that comprehensively covers tumor immunology and immunotherapy. As cancer immunotherapy advances, OncoImmunology is committed to publishing top-tier research encompassing all facets of basic and applied tumor immunology. The journal covers a wide range of topics, including: -Basic and translational studies in immunology of both solid and hematological malignancies -Inflammation, innate and acquired immune responses against cancer -Mechanisms of cancer immunoediting and immune evasion -Modern immunotherapies, including immunomodulators, immune checkpoint inhibitors, T-cell, NK-cell, and macrophage engagers, and CAR T cells -Immunological effects of conventional anticancer therapies.